AstraZeneca confirmed that the late-stage trials of its coronavirus vaccine with the Oxford University were up to 90% effective in preventing the disease.
These results come after the interim analysis of trials in the U.K. and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. Those receiving this vaccine showed no signs of hospitalizations or severe cases of COVID-19.
The trial looked at two different dosing regimens. A half dose of the vaccine followed by a full dose at least one month apart was 90% effective. A second regimen using two full doses one month apart was 62% effective. The combined results showed an average efficacy rate of 70%.
Professor Andrew Pollard, chief investigator for the trial, released a statement and said, “These findings show that we have an effective vaccine that will save many lives.”
“Excitingly, we’ve found that one of our dosing regimens may be around 90% effective.’’